✦ LIBER ✦

Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial

✍ Scribed by Desmond Curran; Carmelo Pozzo; Jerzy Zaluski; Magdalena Dank; Carlo Barone; Vahur Valvere; Suayib Yalcin; Christian Peschel; Miklós Wenczl; Erdem Goker; Roland Bugat

Book ID: 106510371
Publisher: Springer Netherlands
Year: 2009
Tongue: English
Weight: 251 KB
Volume: 18
Category: Article
ISSN: 0962-9343
DOI: 10.1007/s11136-009-9493-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomised phase II trial of weekly hi

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial

✍ M. Ducreux; E. Van Cutsem; J.L. Van Laethem; T.M. Gress; K. Jeziorski; P Rougier 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 128 KB

3502 ORAL Final results of a randomized

3502 ORAL Final results of a randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)

✍ S.E. Al-Batran; J.T. Hartmann; S. Probst; R. Hofheinz; J. Stoehlmacher; C. Pauli 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Quality of life in patients with metasta

Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group

✍ L Hakamies-Blomqvist; M.-L Luoma; J Sjöström; A Pluzanska; M Sjödin; H Mouridsen 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 199 KB

3010 ORAL Final overall survival (OS) re

3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)

✍ J.R. Hecht; T. Trarbach; E. Jaeger; J. Hainsworth; R.A. Wolff; K. Lloyd; G. Bodo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB